Patient organisations are powerful voices when it comes to expressing the opinions and needs of the communities that they represent: they speak for hundreds and even thousands of individuals and families living with a disease.
Novo Nordisk’s R&D Patient Partnering unit facilitates collaboration between patient organisation leaders and Novo Nordisk R&D experts, working across all of our focus areas, including type 1 diabetes, type 2 diabetes, diabetes complications, obesity, haemophilia and growth hormone disorders.
As demonstrated by the EUPATI initiative, patient organisations are increasingly becoming involved in medicine development at the early discovery stage. They provide critical insights and guidance, and offer help and partnership along the R&D path from idea to intervention.
Through DEEPs and tailored, in-depth projects, R&D Patient Partnering connects patient key opinion leaders with Novo Nordisk R&D teams. Not only do these patient leaders have personal disease experience; they also represent a large community of people living with a disease.